Alexander Mm Eggermont
Overview
Explore the profile of Alexander Mm Eggermont including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eggermont A, Kicinski M, Blank C, Mandala M, Long G, Atkinson V, et al.
Eur J Cancer
. 2024 Sep;
211:114327.
PMID: 39288737
Methods: We randomized 1019 patients to receive pembrolizumab 200 mg or placebo, intravenously every 3 weeks for a total of 18 doses. RFS in the overall population and in the...
2.
Di Giacomo A, Lahn M, Eggermont A, Fox B, Ibrahim R, Sharma P, et al.
Eur J Cancer
. 2024 Jan;
198:113501.
PMID: 38169219
The 2022 yearly Think Tank Meeting in Siena, Tuscany (Italy), organized by the Italian Network for Tumor Biotherapy (NIBIT) Foundation, the Parker Institute for Cancer Immunotherapy and the World Immunotherapy...
3.
van Akkooi A, Hauschild A, Long G, Mandala M, Kicinski M, Govaerts A, et al.
Future Oncol
. 2023 Sep;
19(30):2017-2027.
PMID: 37665297
Stage IIB/IIC melanoma has a high risk of recurrence after surgical resection. While, for decades, surgery was the only option for high-risk stage II disease in most countries, adjuvant therapies...
4.
Luke J, Ibrahim N, Eggermont A
Lancet
. 2022 Aug;
400(10352):559-560.
PMID: 35988561
No abstract available.
5.
Eggermont A, Ascierto P, Khushalani N, Schadendorf D, Boland G, Weber J, et al.
Future Oncol
. 2022 Jan;
18(8):903-913.
PMID: 35073733
Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong...
6.
Eggermont A, Meshcheryakov A, Atkinson V, Blank C, Mandala M, Long G, et al.
Eur J Cancer
. 2021 Oct;
158:156-168.
PMID: 34678677
Background: In the phase III double-blind European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 trial, pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with stage III cutaneous melanoma...
7.
Meyer M, Bindelglas E, Kupferman M, Eggermont A
Ecancermedicalscience
. 2020 Oct;
14:ed105.
PMID: 33082857
With major parts of the United States in lockdown, parts of Europe and the UK possibly going back on lockdown or expecting a second COVID-19 wave and rapidly rising rates...
8.
Musoro J, Bottomley A, Coens C, Eggermont A, King M, Cocks K, et al.
Eur J Cancer
. 2018 Oct;
104:169-181.
PMID: 30359910
Introduction: Health-related quality of life (HRQOL) is increasingly recognised as an important end-point in cancer clinical trials. The concept of minimally important difference (MID) enables interpreting differences and changes in...
9.
Bouwhuis M, Ten Hagen T, Suciu S, Eggermont A
Curr Opin Oncol
. 2010 Dec;
23(2):170-6.
PMID: 21150603
Purpose Of Review: Only a subset of melanoma patients with advanced disease seems to benefit from immunotherapy. Predictive markers identifying these patients are unfortunately not available. Whether immune-related side effects...
10.
Deroose J, Eggermont A, van Geel A, Verhoef C
Curr Opin Oncol
. 2010 Dec;
23(2):183-8.
PMID: 21150602
Purpose Of Review: The treatment of in-transit metastasis of melanoma remains challenging and is essentially dictated by the biological behavior of melanoma. When lesions are large or numerous, isolated limb...